Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EBT (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed EBT for 6 consecutive years, with -$78.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 4.25% year-over-year to -$78.6 million, compared with a TTM value of -$220.2 million through Sep 2025, up 14.59%, and an annual FY2024 reading of -$219.1 million, down 5.15% over the prior year.
  • EBT was -$78.6 million for Q3 2025 at Autolus Therapeutics, down from -$47.5 million in the prior quarter.
  • Across five years, EBT topped out at -$7.4 million in Q4 2022 and bottomed at -$82.1 million in Q3 2024.
  • Average EBT over 4 years is -$49.7 million, with a median of -$46.7 million recorded in 2023.
  • The sharpest move saw EBT tumbled 772.39% in 2023, then surged 59.66% in 2024.
  • Year by year, EBT stood at -$7.4 million in 2022, then crashed by 772.39% to -$64.8 million in 2023, then soared by 59.66% to -$26.1 million in 2024, then tumbled by 200.6% to -$78.6 million in 2025.
  • Business Quant data shows EBT for AUTL at -$78.6 million in Q3 2025, -$47.5 million in Q2 2025, and -$67.9 million in Q1 2025.